What does Omicron mean for the future COVID-19 vaccine?

Omicron is spreading at an unprecedented rate, and research on blood samples and emerging real-world evidence suggests that one reason is that it can evade immunity, whether it comes from previous infections or vaccination

Some scientists think this is unnecessary, and they believe that two doses of the current messenger ribonucleic acid (mRNA) vaccine are sufficient to protect most otherwise healthy people from COVID-19

They said that instead of chasing SARS-CoV-2 variants with tailor-made vaccines, it is better to increase efforts.

Céline Gounder New York University School of Medicine Grossman (Grossman School of Medicine), said: "Every six months or even re-enabled once a year, this is not a public health strategy"

Early studies have shown that T cells are largely unaffected by mutations-Immune memory

"Let us give the third dose now to buy us some time while we solve the problem," she said

However, Moderna, which was authorized by the U.

Pfizer and BiotechReported last weekIn a clinical trial, boosted with an mRNA vaccine encoding the alpha peak of an early variant, the level of neutralizing antibodies against Omicron was more than 4 times higher than the level of antibodies raised with beta, delta or alpha/delta mixtures

Regulatory barriers are unclear: Will the FDA or other regulatory agencies simply accept proof of immune response related to protection rather than proof of clinical efficacy?Although studies have shown that neutralizing antibodies are related to protection, other immune responses clearly play a major role: an analysis of a large modern vaccine efficacy test found that neutralizing antibodies accounted for only a part of it68% protection.

He said: "Ao Mike Long wave likely to end in March

Moore is also cautious about companies.

He said: "It will have to as much data as a basis, and some very serious discussions at the government level, rather than let the company executives who find fault with

"Or they have to make vaccines faster," she said

CEPI launched aCall for proposalsTo develop such a vaccine, it is hoped that US$200 million will be invested in these projects in the next five years

He said: "This is a good omen, it is possible to obtain a vaccine can enhance the immune system and resist all diseases

Published as a preprint 4 months ago and published on October 7,NijmWang's research team studied people who recovered from SARS nearly 20 years ago, and they recently received Pfizer's BioNTech COVID-19 vaccine
.
In test-tube studies, their antibodies neutralized SARS-CoV, SARS-CoV-2 and several SARS-related coronaviruses found in bats
.

Wang is currently developing a vaccine booster based on a mixed sequence of SARS-CoV and SARS-related bat viruses, but he has no chance to let monkeys conduct rigorous testing of this concept first
.

He is still going back to the company to buy things
.
"Anything related to business partners takes time," Wang wrote in an email, explaining that he hopes to start clinical trials in the first half of 2022
.
"The emergence of Omicron is expected to make this move faster!"